文献速递神经免疫脑血管病

rs10191329AA携带者多发性硬化残疾进展增加前出现神经丝轻链升高

Increased Disability Progression in rs10191329AA Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
PubMed 文献 · Ann Neurol · 2024-11-26

研究纳入740例多发性硬化患者,其中658例前瞻性每2年随访不足十年,82例回顾性随访至多40年,分析rs10191329风险变异与血清神经丝轻链及残疾进展的关系。纯合携带者随访期sNfL最高、整体残疾指标上升更陡、进展为继发进展型多发性硬化概率更高。

要点

  • 纯合、杂合与非携带者诊断时sNfL水平相当,提示神经轴索损伤相似。
  • 纯合携带者随访期sNfL最高,且出现在后期残疾进展加剧之前。
  • 纯合携带者整体残疾指标上升更陡,进展为继发进展型的概率更高。

核心结论

  • 遗传变异可能作为疾病进展的新生物标志物,用于多发性硬化的个体化医疗和风险评估。

研究设计与样本

  • 队列研究纳入740例多发性硬化患者,其中658例前瞻性每2年随访不足十年,82例回顾性随访至多40年。
  • 采用Kaplan-Meier和Cox比例风险分析临床结局,广义混合效应模型描绘残疾累积,单分子阵列检测sNfL。

主要发现

  • 纯合、杂合与非携带者诊断时sNfL水平相当,提示诊断时神经轴索损伤相似。
  • 纯合携带者随访期sNfL最高,且出现在疾病后期残疾进展加剧之前。
  • 纯合携带者整体残疾指标上升更陡,进展为继发进展型多发性硬化的概率更高。

关键数值与推荐

  • 残疾累积定义:起始EDSS为0者EDSS增加至少1.5分,起始EDSS在1至4.5之间者增加至少1.0分,起始EDSS等于或大于5者增加至少0.5分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined the impact of the rs10191329 genetic risk variant on neuroaxonal damage as measured by serum neurofilament light chain (sNfL) levels, and disability progression in people with multiple sclerosis (pwMS). METHODS: In a cohort of pwMS (n = 740), 658 participants were prospectively monitored every 2 years for less than a decade while 82 of 740 pwMS were monitored retrospectively for up to 40 years. We investigated associations between rs10191329 variants and clinical outcome, including Expanded Disability Status Scale (EDSS), disability accrual (defined by EDSS-increase of at least 1.5 for patients starting at EDSS 0, at least 1.0 EDSS-points for patients with an initial EDSS between 1 and 4.5 and at least 0.5 points for patients starting with an EDSS equal or greater than 5) and progression to secondary progressive MS (SPMS). Clinical outcomes were analyzed using Kaplan-Meier and Cox proportional hazards analyses. Disability accumulation over time was depicted using a generalized mixed-effect model. Single-molecule array was used to assess sNfL levels. RESULTS: Homozygous, heterozygous, and non-carriers of the rs10191329 risk variant displayed comparable sNfL levels indicating similar neuroaxonal damage at the time of diagnosis. Importantly, in homozygous carriers we found highest sNfL levels in follow-up visits preceding elevated disease progression later in the disease course, a steeper increase in overall disability measures and higher probability of SPMS development. INTERPRETATION: These findings highlight how genetic variants may serve as new biomarkers for disease progression and can be used for personalized medicine and risk assessment in MS. ANN NEUROL 2025;97:596-605.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Protopapa M, Steffen F, Schraad M, et al. Increased Disability Progression in rs10191329AA Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations. Ann Neurol. 2024. PMID: 39588882. doi:10.1002/ana.27144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。